Western blotting (Fig 5, S1 Table) showed that BC significantly reduced EGFR, HER-2 and COX-2 protein levels among LS174T cells, as did cetuximab and trastuzumab (P = 0.002). This evidence concerns the gene ERBB2 and breast cancer.